By Dr. John Gebler, Director Strategic Biopharma Business Development The impact of novel biologic modalities on the biopharmaceutical industry as well as on the popular belief of “what’s possible” in Continue Reading
By Dr. John Gebler, Director Strategic Biopharma Business Development The impact of novel biologic modalities on the biopharmaceutical industry as well as on the popular belief of “what’s possible” in Continue Reading